合作類型：技術(shù)     行業(yè)類別: 醫(yī)藥研發(fā)    過期時(shí)間：2016年04月03日    

瑞士大學(xué)已經(jīng)合成了一個(gè)家庭的雙核的芳烴釕(II)配合物(小分子)與高細(xì)胞毒性的癌細(xì)胞。目前正在尋求工業(yè)合作伙以及能進(jìn)一步研發(fā)先導(dǎo)化合物的合作伙伴。

英文原文：A Swiss university has synthesized a family of dinuclear arene ruthenium(II) complexes (small molecules) with high cytotoxicity for cancer cells. Compared to platinum-based, ruthenium-based anti-cancer therapies have shown fewer side effects and similar or higher anti-cancer activity. The university is now seeking an industrial partner to further develop lead compounds. Licensing agreement is sought. Family of dinuclear ruthenium complexes displaying high cytotoxicity in cancer cells - Well-balanced lipophilicity (arene ligands) and hydrophilicity (ionic nature) - Good solubility (chloride salts) and good uptake by cancer cells - Expandable family of compounds - Ruthenium displays 2 more ligand-binding possibilities compared to platinum, allowing for coupling of additional entities to interfere with a variety of biological targets.